A cancer immunogen comprises foreign MHC molecules and additionally one or more oncognes (or constructs that will produce an antigenic region thereof) which can be used to immunize against tumors containing the same or similar oncogenes. Where pathogen-free allogeneic cells are used, it may not be necessary to kill the vaccine before it is administered. The efficacy of the vaccine may be enhanced if the cells also contain immunoenhancing molecules, tumor antigens, or third-party antigens. Cell vaccines containing oncongens can be standardized and used to treat (risk of) specific cancers where there are analogous oncongenes in the tumor or pre-cancerous cells. A panel of such cells covering different oncogenes may be used. The vaccines can be used to immunize prophylactically, in conduction with other therapy, post-surgery or on their own.
